skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

Haanen, J. ; Ernstoff, M.S. ; Wang, Y. ; Menzies, A.M. ; Puzanov, I. ; Grivas, P. ; Larkin, J. ; Peters, S. ; Thompson, J.A. ; Obeid, M.

Annals of oncology, 2020-06, Vol.31 (6), p.724-744 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma

Tan, A.C. ; Emmett, L. ; Lo, S. ; Liu, V. ; Kapoor, R. ; Carlino, M.S. ; Guminski, A.D. ; Long, G.V. ; Menzies, A.M.

Annals of oncology, 2018-10, Vol.29 (10), p.2115-2120 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Jansen, Y.J.L. ; Rozeman, E.A. ; Mason, R. ; Goldinger, S.M. ; Geukes Foppen, M.H. ; Hoejberg, L. ; Schmidt, H. ; van Thienen, J.V. ; Haanen, J.B.A.G. ; Tiainen, L. ; Svane, I.M. ; Mäkelä, S. ; Seremet, T. ; Arance, A. ; Dummer, R. ; Bastholt, L. ; Nyakas, M. ; Straume, O. ; Menzies, A.M. ; Long, G.V. ; Atkinson, V. ; Blank, C.U. ; Neyns, B.

Annals of oncology, 2019-07, Vol.30 (7), p.1154-1161 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma

Dimitriou, F. ; Lo, S.N. ; Tan, A.C. ; Emmett, L. ; Kapoor, R. ; Carlino, M.S. ; Long, G.V. ; Menzies, A.M.

Annals of oncology, 2022-01, Vol.33 (1), p.99-106 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy
Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy

Choong, E.S ; Lo, S ; Fogarty, G.B ; Long, G.V ; Menzies, A.M ; Guminski, A ; Shivalingam, B ; Hong, A

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E710-E711 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma
Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma

Liniker, E ; Kong, B ; Menzies, A.M ; Cooper, A.J ; Kefford, R.F ; Fogarty, G.B ; Guminski, A ; Carlino, M.S ; Wang, T.W ; Long, G.V ; Hong, A

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E635-E635 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma
3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma

Liniker, E ; Kong, B ; Menzies, A.M ; Cooper, A ; Ramanujam, S ; Lo, S ; Kefford, R.F ; Fogarty, G.B ; Guminski, A ; Wang, T.W ; Carlino, M.S ; Hong, A ; Long, G.V

European journal of cancer (1990), 2015-09, Vol.51, p.S664-S664 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate
3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate
Material Type:
Artigo 		Adicionar ao Meu Espaço

3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate

Vilain, R.E ; Kakavand, H ; Menzies, A.M ; Madore, J ; Wilmott, J ; Dobney, R ; Jakrot, V ; Cooper, A.J ; Kong, B ; Lo, S ; Liniker, E ; Saw, R.P ; Thompson, J.F ; Kefford, R ; Carlino, M.S ; Long, G.V ; Scolyer, R.A

European journal of cancer (1990), 2015-09, Vol.51, p.S666-S666 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Novel adjuvant options for cutaneous melanoma
Novel adjuvant options for cutaneous melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Novel adjuvant options for cutaneous melanoma

Dimitriou, F. ; Long, G.V. ; Menzies, A.M.

Annals of oncology, 2021-07, Vol.32 (7), p.854-865 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Immunotherapy use outside clinical trial populations: never say never?
Immunotherapy use outside clinical trial populations: never say never?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Immunotherapy use outside clinical trial populations: never say never?

Rzeniewicz, K. ; Larkin, J. ; Menzies, A.M. ; Turajlic, S.

Annals of oncology, 2021-07, Vol.32 (7), p.866-880 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (83)

Data de Publicação 

De até
Refinar
  1. Antes de2016  (5)
  2. 2016Até2017  (8)
  3. 2018Até2019  (34)
  4. 2020Até2022  (46)
  5. Após 2022  (4)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.